Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort.
Cordeiro de Lima VC, Baldotto CS, Barrios CH, Sobrinho EM, Zukin M, Mathias C, Zaffaroni F, Nery RC, Madeira G, Amadio AV, Coelho JC, Geib G, Simões MF, Castro G Jr. Cordeiro de Lima VC, et al. Among authors: baldotto cs. J Glob Oncol. 2018 Sep;4:1-11. doi: 10.1200/JGO.17.00214. J Glob Oncol. 2018. PMID: 30241276 Free PMC article. Clinical Trial.
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Araujo LH, Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC. Zukin M, et al. Among authors: baldotto cs. J Clin Oncol. 2013 Aug 10;31(23):2849-53. doi: 10.1200/JCO.2012.48.1911. Epub 2013 Jun 17. J Clin Oncol. 2013. PMID: 23775961 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Defining a standard set of patient-centred outcomes for lung cancer.
Mak KS, van Bommel AC, Stowell C, Abrahm JL, Baker M, Baldotto CS, Baldwin DR, Borthwick D, Carbone DP, Chen AB, Fox J, Haswell T, Koczywas M, Kozower BD, Mehran RJ, Schramel FM, Senan S, Stirling RG, van Meerbeeck JP, Wouters MW, Peake MD; Lung Cancer Working Group of ICHOM. Mak KS, et al. Among authors: baldotto cs. Eur Respir J. 2016 Sep;48(3):852-60. doi: 10.1183/13993003.02049-2015. Epub 2016 Jul 7. Eur Respir J. 2016. PMID: 27390281 Free PMC article.
Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective.
Araujo LH, Baldotto CS, Monteiro MR, Aguiar PN, Andrade MC, Longo CL, Batista M, Lima R, Azevedo D, Carvalho N, Andrade P, Zukin M, Teich N. Araujo LH, et al. Among authors: baldotto cs. Future Oncol. 2021 May;17(14):1721-1733. doi: 10.2217/fon-2020-0991. Epub 2021 Feb 25. Future Oncol. 2021. PMID: 33626916 Free article.
13 results